Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of Batoclimab in NMOSD
NCT04227470Phase 1Completed
- Sponsor
- Harbour BioMed
- Start
- Mar 2020
- Primary completion
- Dec 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of batoclimab in Neuromyelitis Optica Spectrum Disorder (NMOSD) (2 arms), sponsored by Harbour BioMed. Primary endpoint: Number of treatment related adverse events (AEs) at 189 days. Started Mar 2020; status: completed.
02
Drugs
batoclimab
03
Conditions
Neuromyelitis Optica Spectrum Disorder (NMOSD)
Beyond the preview
Go deeper on NCT04227470.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04227470.